Abstract
Research on controlled drug delivery for cancer chemotherapy has focused mainly on ways to deliver existing anti-cancer drug compounds to specified targets, e.g., by conjugating them with magnetic particles or encapsulating them in micelles. Here, we show that an iron-salen, i.e., μ-oxo N,N'- bis(salicylidene)ethylenediamine iron (Fe(Salen)), but not other metal salen derivatives, intrinsically exhibits both magnetic character and anti-cancer activity. X-Ray crystallographic analysis and first principles calculations based on the measured structure support this. It promoted apoptosis of various cancer cell lines, likely, via production of reactive oxygen species. In mouse leg tumor and tail melanoma models, Fe(Salen) delivery with magnet caused a robust decrease in tumor size, and the accumulation of Fe(Salen) was visualized by magnetic resonance imaging. Fe(Salen) is an anti-cancer compound with magnetic property, which is suitable for drug delivery and imaging. We believe such magnetic anti-cancer drugs have the potential to greatly advance cancer chemotherapy for new theranostics and drug-delivery strategies.
References
Dec 1, 1994·Journal of the American Academy of Dermatology·A GreenN Knight
Nov 21, 1998·Critical Reviews in Therapeutic Drug Carrier Systems·J A Rogers, K E Anderson
Sep 3, 1999·The Journal of Biological Chemistry·J BaiA I Cederbaum
Oct 16, 1999·Nucleic Acids Research·S RoutierC Bailly
Apr 4, 2000·Journal of Combinatorial Chemistry·A K GhoseJ J Wendoloski
Oct 26, 2002·Physical Review Letters·Giniyat Khaliullin, Satoshi Okamoto
Jan 1, 2005·Biomaterials·Ajay Kumar Gupta, Mona Gupta
Feb 3, 2005·Nature Reviews. Drug Discovery·Vladimir P Torchilin
Jan 5, 2007·Journal of the National Cancer Institute·Ana M PonceMark W Dewhirst
Mar 30, 2007·Proceedings of the National Academy of Sciences of the United States of America·Barbara SteccaAriel Ruiz I Altaba
May 8, 2007·Cancer Cell·Pablo Lopez-BergamiZe'ev Ronai
Aug 25, 2007·Nanomedicine·Etienne DuguetJean-Marie Devoisselle
Dec 25, 2007·Acta Crystallographica. Section A, Foundations of Crystallography·George M Sheldrick
Jan 9, 2008·Journal of Inorganic Biochemistry·Getachew A Woldemariam, Subhrangsu S Mandal
Apr 4, 2008·Nature·Ralph Weissleder, Mikael J Pittet
Sep 8, 2009·Nature Nanotechnology·Yoshihisa NamikiNorio Tada
Sep 15, 2010·Nature Reviews. Clinical Oncology·Rakesh K Jain, Triantafyllos Stylianopoulos
Nov 4, 2010·Journal of Biomolecular Screening·Khairul I AnsariSubhrangsu S Mandal
Nov 19, 2010·Bioanalysis·Dylan M BachWilliam Clarke
Oct 7, 2011·Bioinorganic Chemistry and Applications·Mohammad RezaeeLéon Sanche
Mar 7, 2012·The Journal of Physiological Sciences : JPS·Hidenobu FukumuraTomoyuki Saito
Apr 13, 2013·Endocrine-related Cancer·Xinyu WuZoran Culig
Jul 6, 2013·Scientific Reports·Limor MinaiDvir Yelin
Mar 13, 2014·The Journal of Physiological Sciences : JPS·Itaru SatoYoshihiro Ishikawa
May 9, 2014·Cell Biology International·Nitika PradhanPrasanta K Maiti
Citations
Apr 23, 2016·Scientific Reports·Itaru SatoYoshihiro Ishikawa
Sep 11, 2016·The Journal of Physiological Sciences : JPS·Kayoko OdaYoshihiro Ishikawa
Feb 22, 2017·Scientific Reports·Makoto OhtakeYoshihiro Ishikawa
Aug 30, 2018·Cancer Science·Taisuke AkimotoYoshihiro Ishikawa
Oct 31, 2018·Cancer Science·Masanari UmemuraYoshihiro Ishikawa
Apr 21, 2018·Scientific Reports·Masatoshi NarikawaYoshihiro Ishikawa
Jul 3, 2019·Pharmaceutics·Farinaz KetabatSilvana Papagerakis
Apr 13, 2018·Oncotarget·Rina NakakajiYoshihiro Ishikawa
Nov 13, 2019·Nanotechnology·Prashant KhareySharad Gupta
Apr 25, 2020·Frontiers in Chemistry·Małgorzata ŚwiętekDaniel Horák
Jan 8, 2017·BMC Cancer·Kengo KurodaEmiko Isogai
Oct 24, 2018·Inorganic Chemistry·Kori A AndreaFrancesca M Kerton
Sep 29, 2017··N. V. SvarovskayaO. V. Bakina